Concordance of ATM (ataxia telangiectasia mutated) immunohistochemistry between biopsy or metastatic tumor samples and primary tumors in gastric cancer patients

Pathobiology

Volumn 80, Issue 3, 2013, Pages 127-137

  Kim, Hee Sung ^c   Kim, Min A ^a   Hodgson, Darren ^d   Harbron, Christopher ^d   Wellings, Robert ^d   O'Connor, Mark J ^d   Womack, Christopher ^d   Yin, Xiaolu ^d   Bang, Yung Jue ^b   Im, Seok Ah ^b   Lee, Byung Lan ^b   Kim, Woo Ho ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Gachon University   (South Korea)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Ataxia telangiectasia mutated protein; Biopsy; Immunohistochemistry; Metastatic tumor; Stomach neoplasm

Indexed keywords

ADULT; ARTICLE; ATAXIA TELANGIECTASIA; CANCER PATIENT; CANCER SURGERY; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SPATIOTEMPORAL ANALYSIS; STOMACH CANCER; TISSUE MICROARRAY; TUMOR BIOPSY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; ENDOSCOPIC BIOPSY; INTESTINE METAPLASIA; METASTASIS; OVERALL SURVIVAL; PERINEURAL INVASION; PREVALENCE; STANDARD; STOMACH TUMOR; TISSUE SECTION; TUMOR VOLUME;

ADENOCARCINOMA; BIOPSY; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROTEIN-SERINE-THREONINE KINASES; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

ATAXIA TELANGIECTASIA;

ATM PROTEIN; OLAPARIB;

EID: 84872270312     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000346034     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Lee JH, Paull TT: Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 2007; 26: 7741-7748.
3. de Murcia JM, Niedergang C, Trucco C, Ricoul M, Dutrillaux B, Mark M, Oliver FJ, Masson M, Dierich A, LeMeur M, Walz-tinger C, Chambon P, de Murcia G: Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 1997; 94: 7303-7307.
4. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A: Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011; 12: 852-861.
5. Schaffner C, Idler I, Stilgenbauer S, Döhner H, Lichter P: Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci USA 2000; 97:2773-2778.
6. Williamson CT, Muzik H, Turhan AG, Zamo A, O'Connor MJ, Bebb DG, Lees-Miller SP: ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) poly-merase-1 inhibitors. Mol Cancer Ther 2010; 9: 347-357.
7. Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJS, Smith G, Powell JE, Rudzki Z, Kearns P, Moss PAH, Taylor AMR, Stankovic T: The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 2010; 116:4578-4587.
8. Zhang L, Jia G, Li W-M, Guo R-F, Cui J-T, Yang L, Lu Y-Y: Alteration of the ATM gene occurs in gastric cancer cell lines and primary tumors associated with cellular response to DNA damage. Mutat Res 2004; 557:41-51.
9. Kang B, Guo RF, Tan XH, Zhao M, Tang ZB, Lu Y Y: E x pression st atus of ata x ia-telang iec-tasia-mutated gene correlated with prognosis in advanced gastric cancer. Mutat Res 2008; 638: 17-25.
10. Guo X, Cheng W, Bai Y, Ni X-Z, Shen D, Zhang S, Xie L, Knights C, Lau A, O'Connor M, Yin X, Warford A, Gu Y: ATM deficiency sensitizes gastric cancer cells to the PARP inhibitor olaparib. Mol Cancer Ther 2009; 8:(Meeting Abstract Supplement)B42.
11. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, Mc-Shane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FCG, Taube S, Torlakovic EE, Valen-stein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
12. Hoos A, Urist MJ, Stojadinovic A, Mastorides S, Dudas ME, Leung DH, Kuo D, Bren-nan MF, Lewis JJ, Cordon-Cardo C: Validation of tissue microarrays for immunohisto-chemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 2001; 158:1245-1251.
13. Boone J, Hillegersberg R, Diest PJ, Offerhaus GJA, Borel Rinkes IHM, Ten Kate FJW: Validation of tissue microarray technology in squamous cell carcinoma of the esophagus. Virchows Arch 2008; 452:507-514.
14. Chivukula M, Bhargava R, Brufsky A, Surti U, Dabbs DJ: Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohisto-chemical score 2+) cases. Mod Pathol 2008; 21: 363-368.
15. D'Alfonso T, Liu YF, Monni S, Rosen PP, Shin SJ: Accurately assessing HER-2/NEU status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerat ions add res se d. A m J Surg Pat hol 2010 ; 34: 575-581.
16. Kim MA, Lee H-J, Yang H-K, Bang Y-J, Kim WH: Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and meta-static lesions in gastric carcinoma. Histopa-tholog y 2011; 59: 822-831.
17. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M: AJCC Cancer Staging Manual. New York, Springer, 2002, pp 99-106.
18. Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977; 33:159-174.
19. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E: Gastric cancer. Crit Rev Oncol Hematol 2009; 71: 127-164.
20. Lee S, de Boer WB, Fermoyle S, Platten M, Ku-marasinghe MP: Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology 2011; 59:832-840.
21. Buzin CH, Gatti RA, Nguyen VQ, Wen CY, Mitui M, Sanal O, Chen JS, Nozari G, Men-gos A, Li X, Fujimura F, Sommer SS: Comprehensive scanning of the ATM gene with DOVAM-S. Hum Mutat 2003; 21:123-131.
22. Savitsky K, Sfez S, Tagle DA, Ziv Y, Sartiel A, Collins FS, Shiloh Y, Rotman G: The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet 1995; 4:2025-2032.
23. Apple SK, Lowe AC, Rao PN, Shintaku IP, Moatamed NA: Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer. Mod Pathol 2009; 22: 1151-1159.
24. Brunelli M, Manfrin E, Martignoni G, Miller K, Remo A, Reghell in D, B ersan i S, G obbo S, Eccher A, Chilosi M, Bonetti F: Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol 2009; 131: 678-682.
25. Moeder CB, Giltnane JM, Harigopal M, Molina ro A, Robi nson A, Gel mon K, Hu ntsma n D, Camp RL, Rimm DL, American Society of Clinical Oncology, College of American Pathologists: Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol 2007; 25:5418-5425.
26. Bernasconi B, Chiaravalli AM, Finzi G, Mi-lani K, Tibiletti MG: Genetic heterogeneity in HER2 testing may influence therapy eligi-bi lity. Breast Cancer Res Treat 2012; 133: 161-168.
27. Yang J, Luo H, Li Y, Li J, Cai Z, Su X, Dai D, Du W, Chen T, Chen M: Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal grow th factor receptor (HER) 2 in gastric cancer specimens. Cel l Bio chem Biophys 2012; 62: 221-228.
28. Albarello L, Pecciarini L, Doglioni C: HER2 testing in gastric cancer. Adv Anat Pathol 2011; 18 : 53-59.
29. Tolles J, Bai Y, Baquero M, Harris LN, Rimm DL, Molinaro AM: Optimal tumor sampling for immunostaining of biomarkers in breast ca rcinoma. Breast Cancer Res 2011; 13:R51.
30. Loser DA, Shibata A, Shibata AK, Woodbine LJ, Jeggo PA, Chalmers AJ: Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Ca ncer Ther 2010; 9: 1775-1787.